Clinical effects of α-lipoic acid combined with epalrestat in elderly patients with diabetic peripheral neuropathy
10.3760/cma.j.issn.0254-9026.2017.03.015
- VernacularTitle:α-硫辛酸联合依帕司他治疗老年糖尿病患者周围神经病变的临床疗效
- Author:
Jincheng ZHANG
;
Shiling TANG
;
Lihui WANG
;
Jie YANG
;
Yan ZHANG
- Keywords:
Diabetes mellitus,type 2;
Thioctic acid;
Aldehyde reductase
- From:
Chinese Journal of Geriatrics
2017;36(3):287-291
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To examine the clinical effects of α-lipoic acid(ALA)combined with epalrestat in elderly patients with diabetic peripheral neuropathy(DPN)and its influence on plasma levels of high-sensitivity C-reactive protein(hs-CRP)and homocysteine(Hcy).Methods A total of 120 DPN patients aged over sixty years were randomly divided into the control group and the treatment group with 60 cases in each group.The control group received 0.6 g ALA in 250 ml saline given by an intravenous drip once a day and the treatment group was additionally given 50 mg epalrestat orally three times a day.Both groups were treated for two weeks.Improvement in clinical symptoms,nerve conduction velocity,and peripheral blood levels of hs-CRP and Hcy were compared between the two groups before and after treatment.Results TSS scores of all items and the total scores of the two groups decreased after treatment,with greater margins seen in the treatment group than in the control group(each P＜0.05).NCV increased in both groups after treatment (each P＜ 0.05),with greater increase in the treatment group(each P＜0.05).Levels of hs-CRP and Hcy were significantly reduced (each P＜0.05).A statistically significant difference was observed in hs-CRP(t =2.620,P=0.010) but not in Hcy(t =0.380,P =0.700)between the two groups.Conclusions ALA combined with epalrestat can significantly improve the symptoms of patients with DPN,with better outcomes than ALA alone,and effectively decrease the peripheral blood level of hs-CRP.
